Skip to main content
ZEVRA THERAPEUTICS, INC. logo

ZEVRA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ZVRA ISIN · US4884452065 LEI · 254900CU6T74V18Y1W18 US Manufacturing
Open in API
Filings indexed 830 across all filing types
Latest filing 2018-10-12 Director's Dealing
Country US United States of America
Listing US ZVRA

About ZEVRA THERAPEUTICS, INC.

https://zevra.com/

Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for patients with rare diseases. The company focuses on addressing significant unmet medical needs by combining a data-driven scientific approach with a patient-first perspective. Its portfolio includes commercial products such as MIPLYFFA®, an FDA-approved treatment for Niemann-Pick disease type C (NPC), and OLPRUVA®. Zevra Therapeutics also maintains a late-stage clinical pipeline, specializing in advancing promising medicines that face complex clinical and regulatory challenges for conditions with limited or no available treatments.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2018-10-12 English
FORM 4 SUBMISSION
Director's Dealing
2018-10-09 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a public offering of common stock by KemPharm, Inc. It includes detailed information about the offering terms, underwriting, risk factors, use of proceeds, and company overview. The document is a registration and offering prospectus supplement, which is a capital markets document used to raise funds through equity issuance. It is not a financial report, earnings release, management discussion, or any other type of regulatory filing related to financial results or governance. The content clearly matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2018-10-05 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes details about an underwriting agreement for a public offering of common stock, an exchange agreement involving convertible notes and preferred stock, amendments to articles of incorporation, and a press release about pricing the offering. There are no financial statements or comprehensive financial data presented, but rather disclosures about financing activities and corporate governance changes related to capital structure. The primary focus is on the company's fundraising through a public offering and related agreements. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and capital structure changes. The document length is over 10,000 characters, indicating it is a full filing, not just a brief announcement. Therefore, the appropriate classification is CAP with high confidence.
2018-10-05 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes preliminary financial results for the quarter ended September 30, 2018, details about a proposed public offering of common stock, and an anticipated Exchange Agreement related to convertible notes. It also includes a press release as an exhibit. The document does not contain full financial statements or detailed financial analysis but rather announces financial condition updates and capital raising activities. The primary focus is on the offering and related capital structure changes, not on comprehensive financial reporting or earnings release highlights. Therefore, the document fits best under Capital/Financing Update (CAP).
2018-10-04 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a preliminary prospectus supplement filed pursuant to Rule 424(b)(5) related to a common stock offering by KemPharm, Inc. It includes detailed information about the offering, underwriting, risk factors, use of proceeds, and company overview. The presence of terms like 'prospectus supplement', 'common stock offering', 'underwriting discounts and commissions', and references to SEC registration and effective dates clearly indicate this is a capital raising document. It is not a financial report, earnings release, or management discussion, but rather a detailed financing and securities offering disclosure. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2018-10-04 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.